Data Sheet (Cat.No.T16154)

MS417

Chemical Properties



CAS No. : 916489-36-6

Formula: C20H19ClN4O2S

Molecular Weight: 414.91

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	MS417 (GTPL7512) is an inhibitor of BET-specific BRD4(BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively), with weak selectivity at CBP BRD with IC50 of 32.7 μM.
Targets(IC50)	Epigenetic Reader Domain,HIV Protease
In vivo	BET (Bromodomain and Extra-Terminal domain)-specific bromodomain inhibitor MS417, designed to block BRD4 binding to the acetylated NF-κB, effectively attenuates NF-κB transcriptional activation of proinflammatory genes in kidney cells treated with TNFα or infected by HIV.?MS417 ameliorates inflammation and kidney injury in HIV-1 transgenic mice, an animal model for HIVAN[1].

Solubility Information

Solubility	Ethanol: 50 mg/mL (120.51 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4102 mL	12.0508 mL	24.1016 mL
5 mM	0.482 mL	2.4102 mL	4.8203 mL
10 mM	0.241 mL	1.2051 mL	2.4102 mL
50 mM	0.0482 mL	0.241 mL	0.482 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Zhang G, et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51.

Cheng-Ming, Chiang. Phospho-BRD4: transcription plasticity and drug targeting[J]. Drug Discovery Today Technologies, 2016.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481